Press Releases

NEW YORK, Oct. 28, 2019 /PRNewswire/ -- The reviews are in! New to market lifestyle and fitness brand BootySprout, (www.bootysprout.com/) is going viral with their at-home high resistanc

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented new preclinical data on its lead program ORIC-101 – a selective and potent glucocorticoid receptor (GR) antagonist in Phase

DUBLIN, Oct. 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its subsidiaries, Forest Laboratories, LLC, Forest Laboratories, Inc. and Forest Laboratories Holdings Ltd. (collectively "Forest") have reached a resolution with a plaintiff class of direct purchasers of Namenda, concluding the previously disclosed direct purchaser class actio

SAN FRANCISCO, Oct. 28, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its third quarter 2019 financial results on November 12, 2019, after the market close. The Company will host a conference call at

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for

SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Applicat

- ADVISE clinical trial initiated and enrollment progressing- Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis SAN DIEGO, Oct. 28, 2019 /PRNewswire/ -- 

PLYMOUTH MEETING, Pa., Oct. 28, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network (NCCN®) Oncology Research Program (

NEW YORK, Oct. 28, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today announced key interim findings from the pivotal Phase 3 SIERRA trial of Iomab-B, including feasibility and safety data, at 50% of total patient enrollment. The SIERRA trial (Study of Iomab-B in E

FORT LAUDERDALE, Fla., Oct. 28, 2019 /PRNewswire/ -- CarePredict, the leading AI-powered preventive senior care platform announced today the launch of the third generation